Business
Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Compan
About this update from Genprex, Inc.
[{"type":"text","content":"Advances Relationship and Collaboration with the University of Pittsburgh of the Commonwealth System of Higher Education","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, May 7, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that following the recent completion of its two-year Sponsored Research Agreement (SRA) with the University of Pittsburgh of the Commonwealth System of Higher Education (Pitt) to study Type 1 diabetes (T1D) and Type 2 diabetes (T2D), the parties have entered into a new SRA to study GPX-002, the Company's gene therapy for diabetes, in T1D and T2D in animal models.","length":635,"tagName":"p"},{"type":"image","alt":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","displaySize":"","headline":null,"caption":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. (PRNewsfoto/Genprex, Inc.) (PRNewsfoto/Genprex, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xA37qCr88_2_J9WjJLKhZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f50a341694cf7fe551faa42c59d58c55","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1798169/Genprex_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We continue to make advancements in our studies of GPX-002 in both T1D and T2D, including mouse models, construct optimization and studies in other animal models," said Ryan Confer, President and Chief Executive Officer at Genprex. "As we advance into new animal studies in both T1D and T2D, we look forward to exploring how GPX-002 may decrease insulin requirements and improve glucose tolerance. We believe these studies set us on a path toward human clinical trials."","length":491,"tagName":"p"},{"typ...